Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus reuteri for prevention of necrotising enterocolitis in very low birth weight infants
2008-001324-31Phase 3Terminated
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jun 2008
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Lactobacillus reuteri DSM 17938 in necrotizing enterocolitis (NEC), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Incidence of necrotising enterocolitis stage ≥ II. Started Jun 2008; status: terminated.
02
Drugs
Lactobacillus reuteri DSM 17938
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on 2008-001324-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001324-31.